WO2008014314A3 - Biomarkers of mild cognitive impairment and alzheimer's disease - Google Patents

Biomarkers of mild cognitive impairment and alzheimer's disease Download PDF

Info

Publication number
WO2008014314A3
WO2008014314A3 PCT/US2007/074309 US2007074309W WO2008014314A3 WO 2008014314 A3 WO2008014314 A3 WO 2008014314A3 US 2007074309 W US2007074309 W US 2007074309W WO 2008014314 A3 WO2008014314 A3 WO 2008014314A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
alzheimer
prostaglandin
isomerase
cognitive impairment
Prior art date
Application number
PCT/US2007/074309
Other languages
French (fr)
Other versions
WO2008014314A2 (en
Inventor
Mark A Lovell
Bert C Lynn
Original Assignee
Univ Kentucky Res Found
Mark A Lovell
Bert C Lynn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found, Mark A Lovell, Bert C Lynn filed Critical Univ Kentucky Res Found
Priority to EP07840505A priority Critical patent/EP2054724B1/en
Priority to AU2007279287A priority patent/AU2007279287B2/en
Priority to CA002658895A priority patent/CA2658895A1/en
Priority to AT07840505T priority patent/ATE523785T1/en
Publication of WO2008014314A2 publication Critical patent/WO2008014314A2/en
Publication of WO2008014314A3 publication Critical patent/WO2008014314A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu-Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein.
PCT/US2007/074309 2006-07-25 2007-07-25 Biomarkers of mild cognitive impairment and alzheimer's disease WO2008014314A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07840505A EP2054724B1 (en) 2006-07-25 2007-07-25 Biomarkers of mild cognitive impairment and alzheimer's disease
AU2007279287A AU2007279287B2 (en) 2006-07-25 2007-07-25 Biomarkers of mild cognitive impairment and Alzheimer's disease
CA002658895A CA2658895A1 (en) 2006-07-25 2007-07-25 Biomarkers of mild cognitive impairment and alzheimer's disease
AT07840505T ATE523785T1 (en) 2006-07-25 2007-07-25 BIOMARRKERS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/459,763 US7851172B2 (en) 2006-07-25 2006-07-25 Biomarkers of mild cognitive impairment and alzheimer's disease
US11/459,763 2006-07-25

Publications (2)

Publication Number Publication Date
WO2008014314A2 WO2008014314A2 (en) 2008-01-31
WO2008014314A3 true WO2008014314A3 (en) 2008-10-23

Family

ID=38982288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/074309 WO2008014314A2 (en) 2006-07-25 2007-07-25 Biomarkers of mild cognitive impairment and alzheimer's disease

Country Status (6)

Country Link
US (2) US7851172B2 (en)
EP (2) EP2054724B1 (en)
AT (1) ATE523785T1 (en)
AU (1) AU2007279287B2 (en)
CA (1) CA2658895A1 (en)
WO (1) WO2008014314A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200091961A (en) 2008-01-18 2020-07-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Methods of detecting signatures of disease or conditions in bodily fluids
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
CN102460176B (en) * 2009-05-21 2014-09-24 李荣秀 Process for differential polypeptides detection and uses thereof
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
CN103026298B (en) 2010-05-21 2016-03-16 普林斯顿大学 For strengthen internal field, light absorption, optical radiation, material tests structure and for making and use the method for this structure
US20140154668A1 (en) 2010-05-21 2014-06-05 The Trustees Of Princeton University Structures for Enhancement of Local Electric Field, Light Absorption, Light Radiation, Material Detection and Methods for Making and Using of the Same.
WO2012012694A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US20120040846A1 (en) 2010-07-23 2012-02-16 President And Fellows Of Harvard College Methods of Detecting Diseases or Conditions Using Phagocytic Cells
JP2013538565A (en) 2010-07-23 2013-10-17 プレジデント アンド フェロウズ オブ ハーバード カレッジ Methods for detecting disease or symptom signatures in body fluids
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US20140082769A1 (en) 2011-03-11 2014-03-20 Joost Schymkowitz Molecules and methods for inhibition and detection of proteins
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
WO2013010170A1 (en) 2011-07-14 2013-01-17 Lovell Mark A Process for detection of alzheimer's disease from a serum sample
WO2013154770A1 (en) * 2012-04-10 2013-10-17 The Trustees Of Princeton University Ultra-sensitive sensor
WO2013153461A2 (en) 2012-04-13 2013-10-17 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
SG10201610537VA (en) 2012-06-15 2017-02-27 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
WO2013188846A1 (en) 2012-06-15 2013-12-19 Harry Stylli Methods of detecting diseases or conditions
WO2014164366A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting cancer
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
CN105358979A (en) * 2013-03-15 2016-02-24 普林斯顿大学理事会 Analyte detection enhancement by targeted immobilization, surface amplification, and pixelated reading and analysis
JP6265507B2 (en) * 2013-06-28 2018-01-24 株式会社Ｍｃｂｉ Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using the biomarker
EA035336B1 (en) 2013-12-09 2020-05-29 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити Method for treating aging-associated cognitive disorder or disease
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
MA40636A (en) 2014-09-11 2015-09-11 Colleen Kelly Methods of detecting prostate cancer
EA201890020A1 (en) 2015-06-15 2018-05-31 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити METHODS AND COMPOSITIONS FOR THE TREATMENT OF ASSOCIATED WITH AGING STATES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
WO2006108051A2 (en) * 2005-04-05 2006-10-12 Neurodx, Llc Compositions and methods relating to alzheimer's disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278605A (en) * 1980-06-30 1981-07-14 American Cyanamid Company Heteroalkylenebisanthraquinones
US4728605A (en) 1984-07-31 1988-03-01 Fudenberg Herman H Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same
NZ257215A (en) 1992-10-13 1996-12-20 Univ Duke Diagnosis or prognosis of alzheimers using the presence of apolipoprotein e type 4 as an indicator and apolipoprotein e isoform specific antibodies
AU2823895A (en) 1994-06-09 1996-01-04 Bar-Ilan University Diagnosis of alzheimer disease stage by mononuclear cell cytokine secretions
US5686269A (en) 1994-07-28 1997-11-11 The Mclean Hospital Corporation Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
CN1148600C (en) * 1996-11-26 2004-05-05 三星电子株式会社 Liquid crystal display using organic insulating material and manufacturing methods thereof
AUPO943297A0 (en) 1997-09-24 1997-10-16 University Of Melbourne, The Diagnostic test for alzheimer's disease
US6358681B2 (en) 1998-10-30 2002-03-19 The Trustees Of The University Of Pennsylvania Diagnostic methods for alzheimer's disease by detection of multiple mRNAs
CA2269432C (en) 1998-06-01 2002-04-02 Hyman M. Schipper Ho-1 as a diagnostic and prognostic test for dementing diseases
US6458549B2 (en) 1998-06-11 2002-10-01 Winthrop-University Hospital Methods of diagnosing renal salt wasting syndrome and Alzheimer's disease and methods of treating the same
US6465195B2 (en) 1999-12-30 2002-10-15 Washington University Predictive diagnostic for Alzheimer's disease
US6495335B2 (en) 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
US6475161B2 (en) 2001-03-29 2002-11-05 The Mclean Hospital Corporation Methods for diagnosing Alzheimer's disease and other forms of dementia
US6451547B1 (en) 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
EP1692520A2 (en) 2003-11-19 2006-08-23 Satoris, Inc. Method for diagnosis, stratification and monitoring of alzheimer's disease
JP4772065B2 (en) * 2005-02-19 2011-09-14 ピープルバイオ アイ エヌ シー Method for differential detection of multimeric forms from monomeric forms of multimeric polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
WO2006108051A2 (en) * 2005-04-05 2006-10-12 Neurodx, Llc Compositions and methods relating to alzheimer's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STARK M. ET AL, JOURNAL OF CHROMATOGRAPHY B : BIOMEDICAL APPLICATIONS, vol. 754, no. 2, 2001, pages 357 - 367, XP004232820 *

Also Published As

Publication number Publication date
US7851172B2 (en) 2010-12-14
EP2388591A3 (en) 2012-04-25
AU2007279287A1 (en) 2008-01-31
EP2054724A2 (en) 2009-05-06
CA2658895A1 (en) 2008-01-31
EP2054724A4 (en) 2009-10-28
EP2388591A2 (en) 2011-11-23
AU2007279287B2 (en) 2013-01-17
US20110104724A1 (en) 2011-05-05
WO2008014314A2 (en) 2008-01-31
ATE523785T1 (en) 2011-09-15
US20080026405A1 (en) 2008-01-31
EP2054724B1 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
WO2008014314A3 (en) Biomarkers of mild cognitive impairment and alzheimer's disease
WO2010061283A3 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
WO2007082154A3 (en) B7-h1 and b7-h4 in cancer
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
WO2008039946A3 (en) Integrated meter for analyzing biological samples
WO2008084331A3 (en) Biomarkers for renal disorders
DE602007011566D1 (en) Ankheit
WO2006108112A3 (en) System and method for identifying molecules
EP1776470A4 (en) Reagents, kits and methods for immunodetection of epitopes on molecules
WO2007136980A3 (en) Diagnostic test media and methods for the manufacture thereof
WO2010135574A3 (en) Systems and methods for determining the percentage of glycated hemoglobin
WO2010065781A3 (en) Lateral flow strip assay with immobilized conjugate
WO2008007242A3 (en) Increased specificity of analyte detection by measurement of bound and unbound labels
WO2007092173A3 (en) Raman spectroscopic lateral flow test strip assays
WO2008063770A3 (en) Reducing optical interference in a fluidic device
WO2009026381A3 (en) Method, computer program product and system for individual assessment of alcohol sensitivity
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2010045490A3 (en) Human biomarker hypermapping for depressive disorders
WO2007003801A3 (en) Method and system for measuring and examining reactor fouling
WO2007106762A3 (en) Alzheimer's disease biomarkers and methods of use
WO2007085827A3 (en) Epigenetic analyses
WO2008050291A3 (en) Quantitative measurement of glycated hemoglobin
WO2007126882A3 (en) Analysis of splice variant expression data
WO2008024483A3 (en) Array-based analyte detection
WO2007143531A3 (en) Audible range oculocometry for assessment of vestibular function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07840505

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2658895

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007279287

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007840505

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007279287

Country of ref document: AU

Date of ref document: 20070725

Kind code of ref document: A